Pfizer's fundamental performance has been decent. Read why PFE stock is a Speculative Buy for investors looking for dividend ...

Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25 ...

Threats include intense competition and regulatory pressures.

Healthcare giants Pfizer Inc (NASDAQ:PFE) and AstraZeneca Plc (NASDAQ:AZN) have investments in France, collectively totaling ...

Pfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates.

Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Pfizer CEO Albert Bourla criticized the ...

The company's financial health remains robust, underscored by a decrease in cost of sales and operational efficiencies.

An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $29.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...